ERBB2 and breast cancer: In multivariate analysis (Table 4), molecular markers were grouped in the four molecular sub-types based on the incidence of bone metastases with TNBC as reference, with relative prevalence (RP) and 95% CI for HER-2 enriched, Luminal B and Luminal A: 0.90 (0.49, 1.64), 1.10 (0.69, 1.74) and 0.53 (0.23; 1.23) with p values: 0.732; 0.679; and 0.118, respectively There was no statistically significant correlation between subtype and bone metastases in patients with breast cancer.